New findings presented at AACR 2021! Novel preclinical Inhibigen™ data show pro-tumor effects are detected as early as four days after Inhibigen administration. Insights into Inhibigen biology may yield new therapeutic targets to treat immunotherapy resistance. Learn more in our latest press release.
